



Mitosis in Circulating Tumor Cells Correlates with Highly Aggressive Disease in Metastatic Breast Cancer

Alexis B. Duffy¹, Massimo Cristofanilli², Carolina Reduzzi², William V. Williams³, Giuseppe Del Priore³, Saranya Chumsri⁴, Cha-Mei Tang⁵, Toshiaki Iwase⁶, Naoto T. Ueno⁶, Daniel L. Adams¹

¹Creatv MicroTech, Monmouth Junction, NJ 08852, ²Weill Cornell Medicine, New York, NY 10065, ³BriaCell Therapeutics Corp., Philadelphia, PA 19104, ⁴Mayo Clinic Cancer Center, Jacksonville, FL 32224, ⁵Creatv MicroTech, Inc., Rockville, MD 20850, ⁶University of Hawai'i Cancer Center, Honolulu, HI 96813

ABSTRACT

Circulating tumor cells (CTCs) are a well-known non-invasive blood biomarker which can stratify metastatic breast cancer (mBC) patients, especially those with highly aggressive subtypes. Initial pilot studies have characterized a distinct subtype of CTCs undergoing mitosis, whose presence correlates with worse survival outcomes than CTCs alone. However, their prognostic value and their influence in different therapeutic regimes remains unknown. In a multi-institutional prospective study, we isolated CTCs from n=138 mBC patients to categorize mitotic CTCs, evaluate their association with progression-free survival (PFS) & overall survival (OS) over 2 years, and how their response rates effect different therapeutic strategies.

MATERIALS & METHODS

Peripheral blood samples (7.5ml) were collected from n=138 mBC patients progressing on systemic therapies but prior to new systemic therapies (i.e. chemotherapy n=48, hormone therapy n=17, immunotherapy n=64, targeted therapy n=22). CellSieve microfilters isolated CTCs via size exclusion and cells fluorescently stained for CD45, Cytokeratin, and DAPI. CTCs were imaged, enumerated, and subtyped based on the presence of ≥1 mitotic CTC, using previously established visual indicators. PFS and OS were assessed over 2 years by censored univariate and multivariate analyses. Therapy efficacy was assessed by comparing median PFS (mPFS) and median OS (mOS) in the therapy categories.

Figure 3. Median PFS by Cell Group




Figure 4. Median OS by Cell Group




Figure 1. PFS of CTC Subtypes




Figure 2. OS of CTC Subtypes




Figure 1: PFS					Figure 2: OS				
Time (months)	No. at Risk	No CTCs	CTCs	Mitotic CTCs	Time (months)	No. at Risk	No CTCs	CTCs	Mitotic CTCs
0	77	61	30	31	0	77	61	30	31
6	26	13	11	2	6	51	34	24	10
12	12	7	6	1	12	28	18	13	5
18	5	3	2	1	18	14	9	5	4
24	5	2	1	1	24	13	3	2	1


RESULTS

- Any CTC type was found in 44% of patients (n=61/138), Mitotic CTCs were identified in a subset, 51% (n=31/61)
- Any CTC type was associated with poorer PFS (HR=1.8, p=0.0064) & OS (HR=2.1, p=0.0035) vs without CTCs. Mitotic CTCs had significantly poorer PFS (HR=2.8, p=0.0009) & OS (HR=2.6, p=0.0068) versus non-mitotic CTCs. (Fig. 1 & Fig. 2)
- Both No CTCs & Non-mitotic CTCs have similar response and survival rates independent of therapy. (Fig. 3 & 4)
- Mitotic CTCs had poor PFS to all therapies but longer OS when treated with targeted therapy. (Fig. 3 & 4)

CONCLUSION

- While detection of any CTC type indicated poor outcomes in patients, CTCs undergoing mitosis appears to indicate highly aggressive disease with the poorest survival rates.
- No CTCs and non-mitotic CTCs has similar survival rates to the various therapy types.
- Mitotic CTCs appear to have superior survival benefit when treated with targeted therapy.
- CTC stratification could identify aggressive CTC populations who could benefit from specific therapy types allowing for improved outcomes. (Fig. 5)
- Larger studies are needed to expand upon and validate these preliminary findings.

Figure 5. CTC-Based Patient Stratification



FUNDING SOURCE

This work was supported by the U.S. Army Research Office (ARO) and the Defense Advanced Research Projects Agency (policy of the US Government. DARPA) (W911NF-14-C-0098). The content of the information does not necessarily reflect the position or the policy of the US Government.

REFERENCES

- Adams DL, et al "Mitosis in circulating tumor cells stratifies highly aggressive breast carcinomas." *Breast Cancer Res.* 2016
- Mu et al, Detection and Characterization of Circulating Tumor Associated Cells in Metastatic Breast Cancer" *Int. J. Mol. Sci.* 2016, 17(10), 1665
- Cristofanilli M, "Liquid Biopsies in Solid Tumors" *Springer Intl Publish.* 2017